David Kabakoff, Ph.D., joined Sofinnova Ventures as an Executive-in-Residence in 2007. David has 30 years of experience leading technology and product development programs in the pharmaceutical, biopharmaceutical, and drug delivery fields. He currently serves as Chairman of Trius Therapeutics and Chairman of Amplimmune, Inc. He is also a Director of InterMune, Inc.; Avalon Pharmaceuticals, Inc.; and Alylix, Inc. Dr. Kabakoff also serves as a Board Observer at Intellikine and Anza Therapeutics.
David co-founded Salmedix, Inc., a developer of cancer drug treatments, and served as the company’s Chairman and Chief Executive Officer. In June 2005, David negotiated the acquisition of Salmedix by Cephalon, Inc. David also held the positions of Executive Vice President, President and Chief Executive Officer of Spiros Development Corp. while at Dura Pharmaceuticals, a specialty respiratory pharmaceutical and pulmonary drug delivery company. Earlier, David was also employed as Chief Executive Officer of Corvas International and held senior executive positions with Hybritech, Inc.
David received his Ph.D. from Yale University and his B.A. from Case Western Reserve University.
© 2007-2018, Xconomy, Inc. Xconomy is a registered service mark of Xconomy, Inc. All rights reserved.